Breakthrough in Drug 3D Printing

AJAY KUMAR | July 31, 2017

article image
Recent strides in pharmaceutical 3D printing has revealed that not only does 3D printing take lesser time to produce, but also the new technique forms unique chemical structures that can potentially treat several ailments more effectively than conventionally manufactured drugs.

Spotlight

Pharma Education Center PEC

è una Società che ha come missione l'organizzazione di Corsi in house e pubblici di elevato livello culturale nel settore Life Sciences. Nell’organizzazione di PEC, un ruolo chiave per la realizzazione della missione è affidato ai Working Groups; essi costituiscono una comunità scientifica in divenire, che offre agli iscritti opportunità di nuovi contatti, aggiornamento, scambio e condivisione di informazioni e conoscenze tecnico/scientifiche.

OTHER ARTICLES

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 1, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Top Specialty Pharmacy Therapy Areas

Article | March 16, 2020

Accelerated by advancements in cancer treatments and a growing emphasis on personalized and precision medicine, specialty pharmacy represents a rapidly growing sector within the healthcare industry. In fact, the market is projected to grow to $500 billion by the end of this year—up from $200 billion in total U.S. specialty drug spending in 2017. Industry growth of this magnitude creates challenges for those looking to understand and penetrate the market. It can be difficult, after all, to maintain updated information about high-priority drug therapy areas or facility affiliations in a market that’s constantly changing.

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | March 1, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | February 11, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

Spotlight

Pharma Education Center PEC

è una Società che ha come missione l'organizzazione di Corsi in house e pubblici di elevato livello culturale nel settore Life Sciences. Nell’organizzazione di PEC, un ruolo chiave per la realizzazione della missione è affidato ai Working Groups; essi costituiscono una comunità scientifica in divenire, che offre agli iscritti opportunità di nuovi contatti, aggiornamento, scambio e condivisione di informazioni e conoscenze tecnico/scientifiche.

Events